Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate
- 20 March 2019
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 22 (4) , 569-579
Abstract
Voltage-gated Na+ channels (VGSCs) are functionally upregulated in rat and human prostate cancer (PCa) where channel activity promotes cellular invasiveness in vitro and metastasis in vivo. Ranolazine is a clinically used VGSC inhibitor/anti-anginal drug, which has been shown previously to inhibit breast cancer metastasis in vivo. Using the Dunning model of rat PCa, the effect of ranolazine applied systemically (by gavage) was tested on the development of primary tumours and metastases following subcutaneous inoculation of Mat-LyLu cells into Copenhagen rats. In addition, human prostate tissue microarrays were used to determine VGSC protein expression in cancerous versus non-cancerous tissue. Several public databases were searched to compare Nav1.7/ SCN9A expression levels in ‘normal’ vs. PCa tissues. Ranolazine (2.5 and 5 µM) decreased the number of lung metastases by up to 63%. In contrast, primary tumourigenesis was not affected. Ranolazine also reduced the percentage of cells in the metastases expressing Nav1.7, the main VGSC subtype expressed in PCa, but the expression level was higher. In prostate tissue microarrays, VGSC protein expression was significantly higher in cancerous versus non-cancerous tissue. There was no correlation between the VGSC expression and either prostate-specific antigen or Gleason score. In public databases, little information could be found on Nav1.7 protein expression in PCa. In addition, the database information on Nav1.7 mRNA (SCN9A) expression levels did not correlate with previously reported upregulation in PCa cells and tissues. The main conclusions were (i) ranolazine inhibited metastasis and (ii) it was a subpopulation of cells with particularly high levels of Nav1.7 protein that reached the metastatic sites. These data extend earlier studies and suggest that Nav1.7 expression could serve as a functional biomarker of metastatic PCa and that VGSC blockers may be useful as anti-metastatic agents.Keywords
This publication has 63 references indexed in Scilit:
- Voltage-gated sodium channels and metastatic diseaseChannels, 2012
- Voltage-Gated Na+ Channel SCN5A Is a Key Regulator of a Gene Transcriptional Network That Controls Colon Cancer InvasionCancer Research, 2010
- The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemiaMolecular Cancer, 2010
- Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivoLife Sciences, 2008
- Metastasis Suppressors and Their Roles in Breast CarcinomaJournal of Mammary Gland Biology and Neoplasia, 2007
- Functional expression of voltage‐gated sodium channels in primary cultures of human cervical cancerJournal of Cellular Physiology, 2006
- Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian CellsMolecular & Cellular Proteomics, 2004
- Contribution of functional voltage‐gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. lateral motilityJournal of Cellular Physiology, 2003
- Expression profiles of voltage‐gated Na+ channel α‐subunit genes in rat and human prostate cancer cell linesThe Prostate, 2001
- Differential expression of voltage‐activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitroFEBS Letters, 1995